CN Patent

CN100577663C — 稠合杂环型激酶抑制剂

Assigned to Bristol Myers Squibb Co · Expires 2010-01-06 · 16y expired

What this patent protects

本发明涉及式I及式II所示的化合物，(见右式)包括它们药学上可接受的盐。本发明的化合物可用作为蛋白质激酶抑制剂，且因此而可用于治疗癌症及其它蛋白质激酶介导的疾病。

USPTO Abstract

本发明涉及式I及式II所示的化合物，(见右式)包括它们药学上可接受的盐。本发明的化合物可用作为蛋白质激酶抑制剂，且因此而可用于治疗癌症及其它蛋白质激酶介导的疾病。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN100577663C
Jurisdiction: CN
Classification: —
Expires: 2010-01-06
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.